Trial · NCT03470545
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving A Clinical Response | Mavacamten (MYK-461) | 45 | Participants | ||
| Percentage of Participants Achieving A Clinical Response | Placebo | 22 | Participants | ||
| Changes From Baseline to Week 30 in Post Exercise in LVOT Peak Gradient. | Mavacamten (MYK-461) | -47 | Standard Deviation 40.3 | mmHg | |
| Changes From Baseline to Week 30 in Post Exercise in LVOT Peak Gradient. | Placebo | -10 | Standard Deviation 29.6 | mmHg | |
| Change From Baseline to Week 30 in pVO2 as Assessed by CPET | Mavacamten (MYK-461) | 1.4 | Standard Deviation 3.12 | mL/kg/min | |
| Change From Baseline to Week 30 in pVO2 as Assessed by CPET | Placebo | -0.05 | Standard Deviation 3.02 | mL/kg/min | |
| Proportion of Participants With at Least 1 Class Improvement in NYHA Functional Class From Baseline to Week 30 | Mavacamten (MYK-461) | 80 | Participants | ||
| Proportion of Participants With at Least 1 Class Improvement in NYHA Functional Class From Baseline to Week 30 | Placebo | 40 | Participants | ||
| Change From Baseline to Week 30 in Participant-reported Health-related Quality of Life as Assessed by the KCCQ Score | Mavacamten (MYK-461) | 13.6 | Standard Deviation 14.42 | Scores on Scale | |
| Change From Baseline to Week 30 in Participant-reported Health-related Quality of Life as Assessed by the KCCQ Score | Placebo | 4.2 | Standard Deviation 13.68 | Scores on Scale | |
| Change From Baseline to Week 30 in Participant-reported Severity of HCM Symptoms as Assessed by the HCMSQ Score | Mavacamten (MYK-461) | -2.8 | Standard Deviation 2.68 | Scores on Scale | |
| Change From Baseline to Week 30 in Participant-reported Severity of HCM Symptoms as Assessed by the HCMSQ Score | Placebo | -0.9 | Standard Deviation 2.41 | Scores on Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03470545/results